|

Mevrometostat Clinical Trials

1 actively recruiting trial across 1 location

Also known as: PF-06821497

Pipeline

Phase 3: 1

Top Sponsors

  • Pfizer1

Indications

  • Metastatic Castration Sensitive Prostate Cancer (mCSPC)1
  • Hormone Sensitive Prostate Cancer1
  • Cancer of the Prostate1
  • Prostate Cancer1
  • Cancer1

Chandler, Arizona1 trial

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

Ironwood Cancer & Research Centers

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.